Watchful Waiting in Children with Unifocal Osseous Langerhans Cell Histiocytosis
Authors:
Open Access
- 29 April 2026
- journal article
- Published by Oxford University Press (OUP) in The Oncologist
- Vol. 31 (9)
Abstract
Background: Langerhans cell histiocytosis (LCH) is a rare inflammatory neoplasm most commonly involving bone. However, data on single-system, single-site LCH (SS-s-LCH), particularly with unifocal bone disease, remain limited. Management strategies for unifocal osseous LCH vary globally, and the safety of a watchful-waiting approach is not well-defined. This study aimed to evaluate whether patients with osseous SS-s-LCH can be managed with observation alone without compromising long-term outcomes. Methods: In this retrospective, multicenter study, we enrolled children with biopsy-proven osseous SS-s-LCH from seven centers in the Chinese Children’s Histiocytosis Group, excluding those with central nervous system (CNS)-risk bone lesions. The primary endpoint was 3-year event-free survival (EFS). Events were defined as disease progression or relapse. Results: The cohort included 134 patients with a median follow-up of 36.0 months. Involved sites were cranial bones (n = 37), vertebrae (n = 33), and other bones (n = 64). At final follow-up, 16 patients had experienced an event, yielding a 3-year EFS of 88.1% (95% CI: 81.5–92.5%). Events included new lesions (n = 14) and primary lesion expansion (n = 2), with 93.8% (15/16) occurring within the first 12 months after diagnosis. EFS did not differ significantly by involved site or mutation status. However, patients staged by PET-CT at diagnosis had a significantly higher 3-year EFS (97.6%) than those staged by conventional imaging (83.7%) (p < 0.05). Long-term quality of life was satisfactory in all assessed patients. Conclusion: Watchful waiting is a safe and effective management strategy for children with unifocal osseous SS-s-LCH. Initial staging with PET-CT may be associated with superior event-free survival, highlighting its potential value in refining risk assessment.Keywords
Funding Information
- National Natural Science Foundation of China (82070202)
- National Natural Science Foundation of China (82141119)
- The Beijing Natural Science Foundation (7232058)
- The Beijing Natural Science Foundation (7242053)
- the Capital’s Funds for Health Improvement and Research (2022-2-1141)
- Reform and Development of Beijing Municipal Health Commission
This publication has 47 references indexed in Scilit:
- Discrepancies between F‐18‐FDG PET/CT findings and conventional imaging in Langerhans cell histiocytosisPediatric Blood & Cancer, 2021
- FDG PET‐CT in pediatric Langerhans cell histiocytosisPediatric Blood & Cancer, 2019
- Role of 18F-FDG PET/CT in patients affected by Langerhans cell histiocytosisJapanese Journal of Radiology, 2017
- Langerhans cell histiocytosis (LCH): Guidelines for diagnosis, clinical work‐up, and treatment for patients till the age of 18 yearsPediatric Blood & Cancer, 2012
- Skeletal Langerhans cell histiocytosis in children: Permanent consequences and health‐related quality of life in long‐term survivorsPediatric Blood & Cancer, 2008
- PET-CT in pediatric Langerhans cell histiocytosisPediatric Radiology, 2007
- Reactivation and risk of sequelae in Langerhans cell histiocytosisPediatric Blood & Cancer, 2007
- Vulnerability Factors for Anxiety Disorders in Children and AdolescentsChild and Adolescent Psychiatric Clinics of North America, 2005
- Permanent consequences in Langerhans cell histiocytosis patients: A pilot study from the Histiocyte Society—Late Effects Study GroupPediatric Blood & Cancer, 2004
- Pattern and course of single‐system disease in Langerhans cell histiocytosis data from the DAL‐HX 83‐ and 90‐studyMedical and Pediatric Oncology, 2001